Tenon Medical announced the US Food and Drug Administration concluded a full Quality System Inspection Technique Level 2 Inspection at Tenon Medical. The QSIT inspection, used to assess a medical device manufacturer’s compliance with the Quality System Requirements and related regulations, guides the FDA investigators in performing an efficient and effective inspection, focusing on all key elements of a firm’s Quality Management System. An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic Act and related Acts. Observations are made when in the investigator’s judgement, conditions or practices observed would indicate that the device has been adulterated or is being prepared, packed, or held under conditions whereby it may be come adulterated or rendered injurious to health. At the conclusion of the inspection on November 1, 2023, the FDA investigator determined there was no need to issue Form 483 and the Closing Meeting was completed with no observations or objectionable conditions identified. A final report will be issued to the Company over the coming weeks.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TNON:
- Tenon Medical announces 1-for-10 reverse stock split
- Tenon Medical initiated with a Buy at Maxim
- Tenon Medical announces withdrawal of public offering of common stock
- Tenon Medical files to sell 5.99M shares of common stock for holders
- Tenon Medical announces first patients treated with JIB instrument kit